MOTHERS WILLINGNESS TO VACCINATE THEIR IN-SCHOOL ADOLESCENTS AGAINST HPV INFECTION IN LAGOS STATE NIGERIA.

Introduction: Human Papillomavirus (HPV) vaccine uptake rates for adolescents are still low in Nigeria despite the availability of safe and effective vaccines. The knowledge and attitudes of mothers to HPV infection and vaccines play a role in adolescents HPV vaccination uptake. This study assessed mothers' willingness to vaccinate their in-school adolescents against HPV infection in Lagos State Nigeria. Methods: A cross-sectional descriptive study involving mothers of in-school adolescents was conducted using a multi-stage sampling technique. A self-administered questionnaire was used for data collection. Chi square test was used to determine association between categorical variable and the level of significant was set at 5%. Results: The mean age of the respondents was 43.0 ± 5.8. Majority (92%) had poor knowledge of HPV infection and vaccination. However, majority (79%) of the respondents had a positive attitude to HPV vaccination. More than half (65.8%) of the respondents' were willing to vaccinate their adolescents against HPV. There were statistically significant associations between respondents' number of daughters and attitude about HPV vaccination (p=0.021), previous pap smear screening and willingness to vaccinate their children against HPV (p=0.012) and overall knowledge of HPV vaccination and willingness to vaccinate their children against HPV (p=0.041). Conclusion: There is a need to increase public awareness and health education of mothers on HPV infection and cervical cancer in order to increase HPV vaccine uptake for their children. Health and education sectors can collaborate to achieve this using school-based HPV education programme.

G6PD variant distribution in sub-Saharan Africa and potential risks ofusing chloroquine/hydroxychloroquine based treatments forCOVID-19

Chloroquine/hydroxychloroquine have been proposed as potential treatments for COVID-19. These drugs have warning labels for use in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Analysis of whole-genome sequence data of 458 individuals from sub-Saharan Africa showed significant G6PD variation across the continent. We identified nine variants, of which four are potentially deleterious to G6PD function, and one (rs1050828) that is known to cause G6PD deficiency. We supplemented data for the rs1050828 variant with genotype array data from over 11,000 Africans. Although this variant is common in Africans overall, large allele frequency differences exist between sub-populations. African sub-populations in the same country can show significant differences in allele frequency (e.g. 16.0% in Tsonga vs 0.8% in Xhosa, both in South Africa, p = 2.4 x 10-3). The high prevalence of variants in the G6PD gene found in this analysis suggests that it may be a significant interaction factor in clinical trials of chloroquine and hydrochloroquine for treatment of COVID-19 in Africans.